You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK):特瑞普利單抗在美國FDA生物製品許可申請進展順利
君實生物(01877.HK)(688180.SH)於互動平台上表示,截至目前特瑞普利單抗在美國FDA的生物製品許可申請(BLA)一切順利。類似於生產基地的現場檢查,臨床試驗的現場檢查屬於新藥上市申請評審過程中的一個環節。公司對該申報適應症的臨床研究質量充滿信心,也對相關檢查做好了所有準備。 此外,對於美國醫療組織City of Hope發表文章稱,其研發的癌症藥物AOH1996針對患者的治療情況良好非常有效,且該藥有機會完全治愈部分復發實體瘤癌,君實生物回應指出,該消息確實令人備受鼓舞,但根據公開信息顯示,目前該研究只是臨床前展露出所述的效果,尚未在人體內證實,AOH1996是否在人體內也有如此的抗腫瘤效果,仍然需要臨床試驗的驗證。 君實生物強調,公司研發團隊除了專注自身管線產品的研發推進以及平台技術提升之外,也會持續關注國內外相關的創新藥物技術突破以及研發進展。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account